Certification also includes acceptance under GFCO-governed processes
LANSING, Mich., Dec. 20, 2022 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that it has received the Performance Tested Method Certification from the AOAC Research Institute for its Reveal® 3-D for Gluten test.
The AOAC certification (No. 122201) provides independent validation that the Reveal 3-D for Gluten test meets the AOAC standard for the screening of gluten residues in environmental samples. Also included in this certification is acceptance for use within processes governed by the Gluten Free Certification Organization (GFCO), a program of the Gluten Intolerance Group of North America (GIG). GIG is a 501c3 non-profit organization that empowers the gluten-free community through consumer support, advocacy, and education.
"With this certification, we once again demonstrate the continued reliability of our assays and our commitment to providing trustworthy, dependable solutions for producers around the world," said John Adent, Neogen's President and Chief Executive Officer. "Our customers can confidently utilize our Reveal 3-D for Gluten tests to help gluten-intolerant and allergic customers minimize exposure to allergens."
Neogen's Reveal 3-D for Gluten is a single-step lateral flow immunochromatographic assay that utilizes a simple, rapid methodology to qualitatively detect gluten residues in environmental and food samples as low as 5 parts per million (ppm).
Neogen Corporation develops and markets comprehensive solutions dedicated to food and animal safety, operating with the intention to "Every day, protect the people and animals we care about." The company's Food Safety segment markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases, and sanitation concerns. Neogen's Animal Safety segment is a leader in the development of genomic solutions along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care, and disinfectants, as well as rodent and insect control solutions.
CONTACT: | Max Wolf, Product Manager, Food Allergens |
517.372.9200, ext. 2427, This email address is being protected from spambots. You need JavaScript enabled to view it. |

| Last Trade: | US$6.19 |
| Daily Change: | 0.12 1.98 |
| Daily Volume: | 2,539,688 |
| Market Cap: | US$1.350B |
May 13, 2025 January 21, 2025 January 10, 2025 December 17, 2024 | |

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load